CervoMed Inc.
$6.17
3.81 (161.44%)
CRVO Price Chart
| Basic | |
|---|---|
| Market Cap | $17.99M |
| Price | $6.17 |
| 52 Week Range | 1.8-26.38 |
| Beta | 0.00 |
| Margins | |
| Gross Profit Margin | 30.24% |
| Operating Profit Margin | -165.71% |
| Net Profit Margin | -147.01% |
| Valuation (TTM) | |
| P/E Ratio | -4.69 |
| Price to Sales Ratio | 6.54 |
| Price to Book Ratio | 1.23 |
| PEG Ratio | 0.02 |
Industry
Biotechnology
Sector
Healthcare
Full-Time Employees
8
Website
IPO Date
2008-05-23T00:00:00.000Z
Description
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
Phone
617-744-4400
Address
20 Park Plaza, Boston, MA, 02116, US
CIK
0001053691